XERS (NASDAQ) - Xeris Pharmaceuticals Inc
Exchange: USA Stocks • Country: USA • Currency: USD • Type: Common Stock • ISIN: US98422E1038
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company markets Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. Web URL: https://www.xerispharma.com
Drawdown (Underwater) Chart
External Links for XERS (NASDAQ) - Xeris Pharmaceuticals Inc
| Market Cap. | 387m USD |
| GiC Sector | Health Care |
| GiC Industry | Pharmaceuticals |
| GiC SubIndustry | Pharmaceuticals |
| TER | 0.00% |
| IPO / Inception | 2018-06-21 |
Ratings
| Fundamental | -3.59 |
| Dividend | - |
| Performance 5y | -4.76 |
| Performance TTM | 10.00 |
| Relative Performance | 9.27 |
| Analysts | 4.50 |
| Price / Fair Price TR | 1.56 |
| Price / Fair Price DCF | todo |
Technical
| Growth TTM | 40.48% |
| CAGR 5y | -32.16% |
| CAGR / Mean Drawdown 5y | -0.43 |
| Sharpe Ratio TTM | 0.48 |
| Alpha vs SP500 TTM | 30.71 |
| Beta vs SP500 5y weekly | 1.60 |
| CAPM | 13.12% |
| Average Daily Range % | 7.47% |
| Volatility GJR Garch 1y | 70.91% |
| Max Drawdown 5y | 96% |
| Mean Drawdown 5y | 75.6% |
| Price / SMA 50 | 21.9% |
| Price / SMA 200 | 78.79% |
| Current Volume | 1406.8k |
| Average Volume | 1253.9k |
Dividends
| Rate TTM | 0.00 |
| Yield TTM | 0.00% |
| Div. CAGR 5y | 0.00% |
| Consistency of Dividends all time | 0.0% |